Biguanide

Summary

Biguanide (CHEMBL4297654) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 101.11 Da · C2H7N5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297654
Name	Biguanide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	176517607
ChEBI	CHEBI:3095
Molecular formula	C2H7N5
Molecular weight	101.11
InChIKey	XNCOSPRUTUOJCJ-UHFFFAOYSA-N

SMILES: C(=N)(N)NC(=N)N

IUPAC name: 1-carbamimidoylguanidine

Also known as: Biguanide, Duraplus, BIGUANIDE

Patent coverage: 25,123 distinct patent families (75,136 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 74,363 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	3	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01301833	PHASE3	COMPLETED	Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
NCT01584232	PHASE3	COMPLETED	A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
NCT01777282	PHASE3	COMPLETED	A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT01940965	PHASE3	COMPLETED	Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
NCT05032001	Not specified	UNKNOWN	ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).